Repare Therapeutics Inc. (RPTX)

Market Cap	139.20M
Revenue (ttm)	51.13M
Net Income (ttm)	-93.80M
Shares Out	42.18M
EPS (ttm)	-2.23
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	72,908
Open	3.370
Previous Close	3.360
Day's Range	3.260 - 3.420
52-Week Range	2.980 - 13.850
Beta	0.56
Analysts	Strong Buy
Price Target	17.33 (+425.15%)
Earnings Date	May 7, 2024

About RPTX

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treat...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 19, 2020
• Employees: 179
• Stock Exchange: NASDAQ
• Ticker Symbol: RPTX

Financial Performance

In 2023, RPTX's revenue was $51.13 million, a decrease of -61.21% compared to the previous year's $131.83 million. Losses were -$93.80 million, 222.9% more than in 2022.

Analyst Forecast

According to 3 analysts, the average rating for RPTX stock is "Strong Buy." The 12-month stock price forecast is $17.33, which is an increase of 425.15% from the latest price.

Price Target

$17.33

(425.15% upside)

Analyst Consensus: Strong Buy